glp-1 injections new orleans Study shows rise in weight loss injections, but Louisiana patients face hurdles Life after weight-loss drugs

Section 1: What Is GLP-1

In November 2023, AstraZeneca made a potential $2 billion investment in the expanding anti-obesity medical industry by licensing an experimental pill from China's Eccogene ECC5004, which is part of a class of extremely efficient weight-loss medicines known as GLP-1 receptor agonists in current injectable therapies

This takes about 15 to 30 seconds

Key questions to bring to that conversation: Does the morning timing requirement (for Wegovy) fit my current medication schedule

The STEP (Semaglutide Treatment Effect in People with obesity) 1 trial was a randomized, placebo-controlled trial that evaluated the efficacy of once-weekly subcutaneous (SC) semaglutide 2.4 mg plus lifestyle interventions in adults with obesity without diabetes (n = 1961)

Compounded GLP-1 and dual GIP/GLP-1 receptor agonists: A statement from the American Diabetes Association